-

CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium

  • Four sessions across two days focusing on key drug discovery and development application areas of organ-on-a-chip technologies
  • Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, including Novo Nordisk, Bristol Myers Squibb, and Pharmaron

CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more confident decision-making, today announced the full scientific programme for the 2026 ‘From Insight to Decision’ e-Symposium. Taking place on the 2nd and 8th of December, the event will feature expert-led sessions offering practical, real-world guidance on OOC use within existing R&D strategies.

Launched in response to landmark legislative and regulatory changes accelerating a global shift towards human-relevant technologies in non-clinical research, the e-Symposium has been developed to address researchers’ common questions around adoption of OOC. The program will discuss how OOC models are developed, where the technologies add most value and how these approaches can provide mechanistic insights that support more confident pre-clinical research decision-making.

The free-to-attend event will include four distinct sessions: an OOC masterclass covering the fundamentals, plus application-specific sessions on model development, ADME/DMPK and toxicology. Panel discussions, in-depth presentations, peer case studies and interactive Q&As will be delivered by leaders in the OOC field, including:

  • Dr. Rachelle Prantil-Baun and Dr Dennis McDuffie, Novo Nordisk
  • Dr. Alexa Rizzolo, Bristol Myers Squibb
  • Dr. Emma Arnesdotter, Luxembourg Institute of Science and Technology (LIST)
  • Dr. Felice Mastroleo, Belgian Nuclear Research Centre
  • Dr. Barry Jones, Pharmaron
  • Dr. Clive Roper, Roper Toxicology Consulting
  • Dr. Yassen Abbas, Dr. Emily Richardson and Dr. Gareth Guenigault, CN Bio

Dr Paul Brooks, CEO, CN Bio, said: “Throughout 2026, regulators have laid the foundations for OOC technology to step up as a core decision-making platform for discovery and development pipelines. From Insight to Decision was created to support the next phase of this journey, bringing together the wider OOC community to share experiences, celebrate successes and discuss the challenges facing drug developers today. We’re pleased to invite researchers worldwide to join us in December and discover the benefits that OOC can bring to their own pipelines.”

‘From Insight to Decision’ can be viewed live or on demand for a limited period. View the full agenda or register for a free ticket: https://symposium.cn-bio.com/

Contacts

Media Contact
Lily Jeffery
Email: lily.jeffery@zymecommunications.com

Industry:

CN Bio

Release Versions
English

Contacts

Media Contact
Lily Jeffery
Email: lily.jeffery@zymecommunications.com

More News From CN Bio

CN Bio Awarded Innovate UK Grant to Reduce Animal Use in Pharmacokinetic Studies

CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced it has been awarded £180k grant funding from Innovate UK. Delivered in partnership with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), the funding aims to support new approach methodologies (NAMs) for use in drug development, aligning with the UK Government’s roa...

CN Bio Launches All-in-one Organ-on-a-chip System, PhysioMimix® Core

CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix® Core. Combining the capabilities of CN Bio’s existing suite of instruments, PhysioMimix Core is the first OOC solution to deliver validated performance across single-organ, multi-organ, and higher-throughput configurations within one microphysiological system (MPS). The PhysioMimix brand builds on o...

CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling

CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS) with new PhysioMimix® computational modeling tools. These capabilities have been developed to enhance Absorption, Distribution, Metabolism and Excretion (ADME) profiling, for accelerated drug discovery and development workflows. This launch represents the Comp...
Back to Newsroom